Compare OCUL & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCUL | AZTA |
|---|---|---|
| Founded | 2006 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2014 | 1996 |
| Metric | OCUL | AZTA |
|---|---|---|
| Price | $6.30 | $43.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $25.73 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 2.7M | 876.2K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,990,000.00 | ★ $593,821,000.00 |
| Revenue This Year | N/A | $4.54 |
| Revenue Next Year | $78.78 | $5.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.00 | $15.93 |
| 52 Week High | $16.44 | $50.06 |
| Indicator | OCUL | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 61.15 |
| Support Level | $6.12 | $31.51 |
| Resistance Level | $7.64 | $46.41 |
| Average True Range (ATR) | 0.42 | 2.50 |
| MACD | 0.06 | 0.74 |
| Stochastic Oscillator | 22.79 | 65.21 |
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.